We are live on
!
Find out more
Creative Planning Portfolio holdings
AUM
$147B
1-Year Est. Return
18.73%
This Fund
S&P 500
This Quarter
Est. Return
+10.9%
1 Year Est. Return
+18.73%
3 Year Est. Return
+48.71%
5 Year Est. Return
+44.71%
10 Year Est. Return
+145.34%
AUM
$27.8B
AUM Growth
+$3.36B
(+14%)
Cap. Flow
+$723M
Cap. Flow
% of AUM
2.6%
Top 10 Holdings %
Top 10 Hldgs %
55.63%
Holding
2,156
New
217
Increased
776
Reduced
764
Closed
175
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core US Aggregate Bond ETF
AGG
|
+$157M |
| 2 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
+$117M |
| 3 |
State Street SPDR Portfolio S&P 400 Mid Cap ETF
SPMD
|
+$105M |
| 4 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$94M |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$93.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Mid-Cap ETF
VO
|
+$63.3M |
| 2 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$32.3M |
| 3 |
Schwab US REIT ETF
SCHH
|
+$21.3M |
| 4 |
Vanguard Energy ETF
VDE
|
+$18.8M |
| 5 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$12.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 4.74% |
| 2 | Technology | 4.11% |
| 3 | Healthcare | 2.19% |
| 4 | Energy | 2.03% |
| 5 | Consumer Discretionary | 1.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1651
TherapeuticsMD
TXMD
$23.8M
| $139K | ﹤0.01% |
572
+240
| +72% | +$63.5K |
|
|
SXCP
1652
DELISTED
SunCoke Energy Partners, L.P.
SXCP
| $138K | ﹤0.01% |
11,100
-200
| -2% | -$2.67K |
|
1653
BGC Group
BGC
$5.58B
| $137K | ﹤0.01% |
25,809
+2,135
| +9% | +$12.7K |
|
1654
Cemex
CX
$17.4B
| $136K | ﹤0.01% |
29,350
-7,879
| -21% | -$39.4K |
|
1655
Graphic Packaging
GPK
$3.26B
| $135K | ﹤0.01% |
+10,660
| New | +$129K |
|
1656
Sterling Infrastructure
STRL
$20.3B
| $135K | ﹤0.01% |
10,750
| – | – |
|
|
AAIC
1657
DELISTED
Arlington Asset Investment Corp.
AAIC
| $134K | ﹤0.01% |
16,882
-11,000
| -39% | -$91K |
|
1658
IGC Pharma
IGC
$27.6M
| $133K | ﹤0.01% |
+64,039
| New | +$146K |
|
|
PPT
1659
Franklin Premier Income Trust
PPT
$326M
| $133K | ﹤0.01% |
25,794
-5,975
| -19% | -$29.8K |
|
|
RCS
1660
PIMCO Strategic Income Fund
RCS
$243M
| $133K | ﹤0.01% |
12,642
+200
| +2% | +$2.03K |
|
|
EIM
1661
Eaton Vance Municipal Bond Fund
EIM
$492M
| $132K | ﹤0.01% |
+10,640
| New | +$125K |
|
|
NCV
1662
Virtus Convertible & Income Fund
NCV
$374M
| $132K | ﹤0.01% |
5,079
-7,175
| -59% | -$177K |
|
1663
Pearson
PSO
$9.78B
| $132K | ﹤0.01% |
12,006
-1,000
| -8% | -$11.7K |
|
|
HTT
1664
High Templar Tech Ltd
HTT
$377M
| $129K | ﹤0.01% |
+25,522
| New | +$136K |
|
1665
SFL Corp
SFL
$1.59B
| $129K | ﹤0.01% |
10,472
-38
| -0.4% | -$459 |
|
1666
Viavi Solutions
VIAV
$9.75B
| $129K | ﹤0.01% |
10,398
-256
| -2% | -$3K |
|
|
ZTR
1667
Virtus Total Return Fund
ZTR
$340M
| $129K | ﹤0.01% |
11,999
+213
| +2% | +$2.18K |
|
1668
CALL
Salesforce
CRM
$134B
| $128K | ﹤0.01% |
5,300
+3,400
| +179% | +$527K |
|
1669
Opko Health
OPK
$921M
| $126K | ﹤0.01% |
48,119
-1,300
| -3% | -$3.94K |
|
|
BCIC
1670
BCP Investment Corp
BCIC
$86.9M
| $126K | ﹤0.01% |
3,487
+600
| +21% | +$21.3K |
|
1671
Global X MLP ETF
MLPA
$2.28B
| $125K | ﹤0.01% |
2,352
-567
| -19% | -$29.5K |
|
1672
Apyx Medical
APYX
$165M
| $124K | ﹤0.01% |
+19,698
| New | +$152K |
|
1673
CALL
Lam Research
LRCX
$382B
| $123K | ﹤0.01% |
100,000
-2,000
| -2% | -$33.4K |
|
|
BNBX
1674
DELISTED
BNB PLUS CORP
BNBX
| – | – |
0
| – | – |
|
|
CTST
1675
DELISTED
CannTrust Holdings Inc. Common Share
CTST
| $119K | ﹤0.01% |
+15,310
| New | +$139K |
|
Similar funds
Creative Planning's Q1 2019 Portfolio in Review
As of Q1 2019, Creative Planning held 2,156 positions worth $27.8B, up 14% from $24.4B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Creative Planning's Q1 2019 filing shows 217 new, 776 increased, 764 reduced and 175 closed positions. Its largest new stake was Intercept Pharmaceuticals, Inc.: 33,175 shares worth $3.71M. The largest sale was Vanguard Mid-Cap ETF, an estimated $63.3M.
By sector, the portfolio is most concentrated in Financials at 4.7% of assets, down from 5.2% a quarter earlier, followed by Technology and Healthcare.
- Creative Planning's largest Q1 2019 buy was Intercept Pharmaceuticals, Inc.: 33,175 shares worth $3.71M.
- Creative Planning added most to iShares Core US Aggregate Bond ETF in Q1 2019, an estimated $157M increase.
- Creative Planning's biggest Q1 2019 reduction was Vanguard Mid-Cap ETF, cutting an estimated $63.3M.
- Creative Planning fully exited Kforce in Q1 2019, selling an estimated $3.23M.
- Creative Planning's ten largest holdings make up 56% of its $27.8B portfolio in Q1 2019.
- Creative Planning opened 217 new positions and closed 175 in Q1 2019.
- Creative Planning's portfolio value rose 14% quarter-over-quarter to $27.8B.
Based on Creative Planning's 13F filing for Q1 2019, filed 24 Apr 2019.